Design and Evaluation of (223)Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution

Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel therapies, the mortality rate remains high. An attractive alternative for extension of the life of mCRPC patients is PSMA-based targeted radi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lankoff, Anna, Czerwińska, Malwina, Walczak, Rafał, Karczmarczyk, Urszula, Tomczyk, Kamil, Brzóska, Kamil, Fracasso, Giulio, Garnuszek, Piotr, Mikołajczak, Renata, Kruszewski, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198605/
https://www.ncbi.nlm.nih.gov/pubmed/34071854
http://dx.doi.org/10.3390/ijms22115702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198605/
https://www.ncbi.nlm.nih.gov/pubmed/34071854
http://dx.doi.org/10.3390/ijms22115702

Ejemplares similares